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Abstract: Giardia lamblia is the causative agent of giardiasis, one of the most common parasitic 
infections of the human intestinal tract. This disease most frequently affects children causing 
abdominal pain, nausea, vomiting, acute or chronic diarrhea, and malabsorption syndrome. 
In undernourished children, giardiasis is a determining factor in retarded physical and mental 
development. Antigiardial chemotherapy focuses on the trophozoite stage. Metronidazole and 
other nitroimidazoles have been used for decades as the therapy of choice against giardiasis. In 
recent years many other drugs have been proposed for the treatment of giardiasis. Therefore, 
several synthetic and natural substances have been tested in search of new giardicidal com-
pounds. This study is a review of drugs used in in vitro and in vivo tests, and also drugs tested 
in clinical trials (nonrandomized and randomized).
Keywords: Giardia lamblia; treatment; new drugs
Introduction
Giardia lamblia (syn. Giardia intestinalis, Giardia duodenalis) is a flagellate protozoan 
which may be found infecting the human small intestine, causing a disease called 
giardiasis. The symptomatology of human giardiasis is extremely variable, many 
individuals have the asymptomatic form while some have abdominal pain, nausea, 
acute or chronic diarrhea – which may last several months, malabsorption and weight 
loss.1–3 The clinical impact seems to be stronger in the first three years of life and in 
undernourished or immunodeficient individuals.4 G. lamblia has often been pointed out 
as the cause of growth disorders among children,3 also with the presence and frequency 
of diarrhea, for as long as the infection lasts, and the opportunity of reinfection, all 
constituting essential factors behind children’s physical and mental debilitation.5
G. lamblia is found in mammals, including human beings, cats, dogs, beavers, and 
cattle. Giardiasis is transmitted by the ingestion of cysts present in food and water; 
water dissemination being easier due to cysts resistance to chlorination.6,7 Cysts are 
highly infectious to men. Human volunteers have been experimentally infected with 
as few as 10 cysts.8 These cysts may remain viable in the environment for up to three 
months under favorable conditions of temperature and humidity. Three aspects are 
important in the epidemiological context of the disease: the cysts’ resistance to the 
environment, the amount of cysts eliminated by the patients, and the zoonotic aspect 
of the disease.9
Epidemics, in developed countries, have been attributed to an inappropriate water 
treatment, to its contamination with human or animal feces, particularly in surface Biologics: Targets & Therapy 2009:3 274
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water collections and lakes.9 Direct transmission from person 
to person is another infection mechanism, particularly impor-
tant in collective institutions, such as daycare centers and 
orphanages, among members of the same family, and between 
male homosexual partners.10 In these populations, giardiasis 
reaches epidemic levels. G. lamblia has a cosmopolitan 
distribution with an estimated number of 2.8 × 108 cases of 
infections per year and is thus the most common intestinal 
parasite in humans in developed countries.11 In Asia, Africa, 
and Latin America, about 200 million people have symptom-
atic giardiasis with some 500,000 new cases reported each 
year.12 In those countries this disease should be observed care-
fully, for it contributes substantially to generating mentally 
and physically impaired adults.
Thompson and colleagues13 reviewed publications by sev-
eral authors who reported genetic variations among Giardia 
samples isolated from human beings. Such differences are 
believed to significantly influence giardiasis epidemiology 
and control, particularly for host susceptibility, virulence, drug 
sensitivity, antigenicity, and in vivo and in vitro development.5 
Although some advances have been observed in isolating and 
characterizing Giardia samples, there are few studies regarding 
this parasite`s chemotherapy.14 Resistance to different drugs 
used in the treatment of this disease has been reported and the 
number of cases is likely to increase.15–17
A variety of chemotherapeutic agents such as 5-nitroimidazole 
compounds, quinacrine, furazolidone, paromomycin, benz-
imidazole compounds, nitazoxanide have been used in the 
therapy for giardiasis. Nevertheless, therapeutic regimens and 
therapy reviews are little explored. Most drugs used have 
considerable adverse effects and, most of the time, they are 
contraindicated.18–20 Furthermore, Giardia seems to have a 
great ability to resist these agents.17,19,21,22
In this context, the study of new chemotherapeutic agents 
plays a fundamental role – along with the reviews of the actu-
ally used drugs – in the rationale for treatment of giardiasis 
on the basis of more consistent data.
Many compounds have shown giardicidal activity in 
in vivo models or in animal models. In the present review, we 
have systematically addressed the main in vitro and in vivo 
studies and prospective trials in human population concerning 
the treatment of giardiasis.
Methodology
This is a review of giardiasis treatment in which we 
analyze the quality of the studies published in the Medline, 
PubMed, and EMBASE databases from 1966 to September, 
2008.
Concentrating only on studies published in English, for 
each class of study (see below), we looked up the following 
key words in various combinations: giardia, giardiasis, treat-
ment, therapeutic, therapy, drug, medication, phytotherapy, 
and chemotherapy. In those studies performed in humans, 
we did not have an age limit and searched for children and 
adult patients.
The studies were divided into four classes. Group I: 
in vitro studies; group II: in vivo studies; group III: clinical 
trials, nonrandomized, controlled or not; group IV: random-
ized control trials (RCT), blinded or not.
inclusion criteria
We included the following studies: In vitro studies consisting 
of studies that tested the sensitivity and efficacy of the drugs 
against Giardia; In vivo studies consisting of studies that 
tested the efficacy of drugs against Giardia in experimental 
animals; Nonrandomized clinical trials consisting of studies 
that tested the efficacy of drugs against Giardia in humans; 
Randomized controlled clinical trials (RCT) consisting of 
studies designed to compare the efficacy between different 
drugs, between drugs and placebo, or to compare different 
schemes of the same drug in humans. These studies were 
necessarily randomized and controlled, but not necessarily 
blinded.
This review was made using two independent reviewers 
following the same inclusion criteria for searching the 
articles simultaneously. After they were finished, the 
reviews were analyzed. Those articles showing up in two 
reviews were automatically included in the final analysis. 
The remaining nonconsensual studies were analyzed by a 
third reviewer for a final decision as to include or exclude an 
article after the discussion between the first two reviewers 
was exhausted.
Statistical analysis
Data are presented as mean ± standard deviation (confidence 
interval [CI]), absolute numbers, or percentages. Compari-
sons between rates of cure of drugs were made using the 
chi-squared or the Student t-test methods. Only variables 
with p < 0.05 were considered significant.
Main results
In the initial search, 116 in vitro studies, 48 in vivo studies, 
87 nonrandomized clinical trials, and 47 RCT were found. 
After selection for the inclusion criteria, 39 in vitro studies, 
nine in vivo studies, 23 nonrandomized clinical trials, and 
34 RCTs remained (Tables 1–4).Biologics: Targets & Therapy 2009:3 275
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Table 1 in vitro studies
Year Drugs/Substances Activity Reference
1975 2,2-biimidazole Yes 23
1983 Human milk Yes 24
1984 Metronidazole
Tinidazole
Furazolidone
Quinacrin
Yes
Yes (+ effective)
Yes
Yes (- effective)
61
1985 Bithionol
Dichlorophene
Hexachlorophene
Yes
Yes
Yes
25
1985 Clomipramine Yes 26
1986 Furazolidone Yes 27
Nitroimidazole Yes
1990 Azitromicin/Furazolidone
Doxiciclin/Mefloquin
Doxiciclin/Tinidazole
Mefloquin/Tinidazole
Yes
Yes
Yes
Yes
28
1991 Metronidazole
Ornidazole
Yes
Yes
29
1991 Azitromicin Yes 30
1994 Serum immune specific Yes 31
1994 Agglutinin of wheat germ Yes 32
1994 Derivatives of allicin (diallyl trisulfide) Yes 60
1995 Phytotherapics popular in Africa
Methanolic extracts cathartics
Methanolic extracts noncathartics
Yes (+ effective)
Yes (- effective)
33
1995 Albendazole
Metronidazole
Yes (- effective)
Yes (+ effective)
34
1999 Derivatives of flavonoid Helianthenum glomeratum Yes 59
2001 Pyrantel pamoate Yes 35
2001 Powder of Yucca schidigera Yes 36
2001 Ciprofloxacin Yes 37
2002 Nitazoxanide
Albendazole
Metronidazole
Yes (+ effective)
Yes (+ effective)
Yes (- effective)
38
2002 Mucin Yes 39
2002 Derivatives of isoflavone Yes 40
2003 Derivative etylphenylcarbamate
Albendazole
Yes (- effective)
Yes (+ effective)
41
2004 Gangliosides Yes 42
2004 Derivate phenyl-carbamate
Albendazole
Yes (- effective)
Yes (+ effective)
43
2004 S-substituted 4,6-dibromo-mercaptobenzimidazole
S-substituted 4,6-dichloro-2-mercaptobenzimidazole
Yes
Yes
58
2005 Dodecanoic acid
Metronidazole
Yes
Yes
44
2005 Arsenic sodium No 45
2005 Derivatives of Artemisia ludoviciana Yes 57
2005 Derivatives of flavonoid glycosides Yes 56
2006 Derivatives benzimidazoles
Albendazole
Metronidazole
Yes (+ effective)
Yes (++ effective)
Yes (- effective)
46
(Continued)Biologics: Targets & Therapy 2009:3 276
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In the 39 in vitro studies selected, 55 drugs were tested, 
53 (96.4%) showed activity against giardia. Eighteen studies 
(46.2%) did not have comparative design with other drugs. 
Twenty-one studies (53.8%) compared activity between 
drugs: 11 (52.4%) compared activity between two drugs, 
and 10 (47.6%) compared activity between three or more 
drugs.
The most frequently tested drugs in in vitro studies 
were: metronidazole (nine studies, 16.4%), albendazole 
(five studies, 9.1%), furazolidone (four studies, 7.3%), 
azitromicyn, nitazoxanide, phenyl-carbamate derivatives, 
tinidazole, and kaempferol (two studies each, 3.6%). The 
other drugs had one study each (Table 5).
In the nine in vivo studies selected in which nine drugs were 
tested, eight (88.9%) showed activity against Giardia. One of 
them compared the efficacy between two drugs (11.1%), and 
the remaining study tested just one drug (Table 2).
Out of the 23 nonrandomized clinical trials, six studies 
(26.1%) had design to compare efficacy between drugs, three 
(13%) compared different schemes of the same drug, and 
three (13%) compared efficacy between one drug and placebo 
(nonrandomized). Eleven studies evaluated the effect of one 
drug without comparing either dosages or efficacy between 
drugs (see Table 3).
Twelve drugs have been tested in the 23 nonrandomized 
clinical trials, with an average sample size of 83.3 ± 53.3 
patients per study (confidence interval [CI] = 57.2 to 109.4). 
The mean general rate of cure (RC) per drug was 85.5% ± 16.7 
(CI = 80.0 to 91.0). The most frequently tested drugs were: 
metronidazole (nine studies, 39.1%), tinidazole (seven studies, 
30.4%), ornidazole, and quinacrine (three studies each, 13%), 
secnidazole, furazolidone, and berberine (two studies each, 8.7%) 
(Table 7). In evaluating drug effectiveness, the following 
mean rates of cure were found: secnidazole (RC = 96% ± 2.8), 
ornidazole (RC = 93.6% ± 1.2), tinidazole (RC = 89.1% ± 8.8), 
Table 2 In vivo studies
Year Drugs/Substances Activity Reference
1991 Albendazole Yes 62
1993 New oxadiazoles
Metronidazole
Yes (+ effective)
Yes (- effective)
63
1996 ivermectin Yes 64
1998 Disulfiram (Antabuse) Yes 65
2000 Oxifendazole Yes 66
2001 ivermectin Yes 67
2002 inmunoglobulin (igA) Yes 68
2003 vaccine against Giardia No 69
2007 Antioxidant (Antox) No 70
Table 1 (Continued)
Year Drugs/Substances Activity Reference
2006 Nitrotiazol (Nitazoxanide)
Metronidazole
Yes
Yes
47
2006 venom Crotalus durissus terrificus
venom Bothrops jararaca
Yes
Yes
48
2006 Propolis Yes 49
2006 Curcumin Yes 50
2006 Metronidazole
Furazolidone
Yes
Yes (+ effective)
55
2006 Dorstenia contrajerva
Senna villosa
Ruta chalepensis
Yes
Yes
Yes
54
2007 Metronidazole
Analogous MTZ-Ms
Analogous MTZ-i
Analogous MTZ-Br
Analogous MTZ-N3
Analogous MTZ-NH3Cl
Yes (- effective)
Yes
Yes
Yes
Yes
Yes
51
2007 extracts of blueberry Yes 52
2007 Tiliroside
Kaempferol-glucopyranoside
Astragalin
Quercitrin
Isoquercitrin
Yes (+ effective)
Yes
Yes
Yes
No
53Biologics: Targets & Therapy 2009:3 277
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Table 3 Nonrandomized clinical trials
Year Drugs/Substances Activity Reference
1972 Berberine Yes 71
1975 Berberine Yes 72
1977 Metronidazole
Tinidazole
Nimorazol
Furazolidone
Yes
Yes
Yes
Yes (- effective)
73
1978 Tiberal 1 g BiD – G1
Tiberal 50 mg/Kg/single dose – G2
Yes
Yes
Se  group G2
74
1978 Metronidazole in four dosage schedules Yes (+ effective in extended systems) 75
1978 Metronidazole
Tinidazole
 
Yes (- effective)
Yes (+ effective)
Se  with metronidazole
76
1978 Tinidazole
Placebo
 
Yes (+ effective)
77
1978 Tinidazole single dose highest
Tinidazole seven days dose lower
 
Yes (+ effective)
Yes (- effective)
78
1979 Metronidazole
Quinacrine
 
Yes (+ effective)
Yes (- effective)
79
1979 Ornidazole  
Yes
80
1980 Metronidazole seven days
Meronidazole single dose
Quinacrine
Tinidazole
Ornidazole
 
Yes (- effective)
Yes (- effective)
Yes (+ effective)
Yes (+ effective)
Yes (+ effective)
Se  with ornidazole
81
1981 Furazolidone
Quinacrine
 
Yes (+ effective)
Yes (- effective)
Se  with quinacrine
82
1987 Metronidazole
Tinidazole
Ornidazole
 
Yes
Yes
Yes
Similar
83
1987 Tinidazole efficiencies 84
1995 Metronidazole Yes 85
1997 Metronidazole + diloxanide Yes 86
1997 Pippali rasayana
Placebo
Yes
 
Yes
87
1998 Albendazole 88
1999 Secnidazole Yes 89
2000 Secnidazole Yes 90
2008 Metronidazole Yes
Yes
91
Abbreviations: BiD, twice a day; Se, side effects.Biologics: Targets & Therapy 2009:3 278
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Table 4 randomized controlled clinical trials
Year Drugs Activity Reference
1970 Mepacrine
Metronidazole
Furazolidone
– 92
1977 Tinidazole
Metronidazole
Yes (+ effective and  Se) 
Yes (- effective and  Se)
93
1978 Tinidazole
Metronidazole
– 94
1978 Tinidazole
Placebo
Yes (+ effective) 95
1981 Tinidazole
Metronidazole
Yes – Similar efficacy 96
1985 Tinidazole
Metronidazole
Yes – Similar efficacy 
with appropriate doses
97
1989 Furazolidone
Placebo
Yes 98
1989 Metronidazole
Furazolidone
Yes
Yes
99
1989 Menbedazole No 100
1990 Metronidazole
Menbendazole
Yes
Yes
101
1991 Metronidazole
Ornidazole
Yes – Similar efficacy 102
1992 Metronidazole
Mebendazole
Yes
Yes
103
1994 Metronidazole
Albendazole
effectiveness of cure similar 
Se  with metronidazole
104
1995 Metronidazole
Albendazole
Yes
Yes
105
1995 Bacitracin zinc
Bacitracin
Neomycin
Neomycin + Bacitracin zinc
Yes
Yes
Yes
Yes
106
1995 Metronidazole single dose
Metronidazole for five days
Albendazole for five days
Yes
Yes
Yes
107
1995 Metronidazole
Ornidazole
Mebendazole
Yes (effective)
Yes (+ effective)
Yes (- effective)
108
1999 Albendazole
Tinidazole
Yes (+ effective)
Yes (- effective)
109
2001 Metronidazole
Mebendazole
Yes
Yes
110
2001 Nitazoxanide
Placebo
Yes (+ effective) 111
2001 Metronidazole
Nitazoxanide
Yes – Similar efficacy 112
2001 Metronidazole + wheat germ
Metronidazole + Placebo
Yes (+ effective)
Yes (- effective)
113
2002 Albendazole
Albendazole + Praziquantel
Tinidazole
Yes (+ effective)
Yes (- effective)
Yes (+ effective)
Albendazole and Tinidazole 
with similar effectiveness
114
(Continued)Biologics: Targets & Therapy 2009:3 279
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quinacrine (RC = 85% ± 21.6), furazolidone (RC = 82% ± 14), 
and metronidazole (RC = 76.6% ± 20.6) (Table 8). The metro-
nidazole was the most studied and tested drug for the giardiasis 
treatment. This drug had greater efficacy in larger doses and in 
more prolonged regimes (5 to 10 days), and achieved a cure rate 
of 87% to 100% in these schemes (Table 9).
Out of the 34 RCTs selected for analysis, 23 studies 
(67.6%) had design to compare efficacy between drugs, 
five (14.7%) compared different schemes of the same drug, 
and five (14.7%) compared efficacy between one drug and 
placebo (randomized). One study tested a drug without com-
paring it with any other drug or placebo. Eight studies (23.5%) 
were double-blind studies, five (62.5%) compared one drug 
with placebo, while three (37.5%) compared the efficacy 
between drugs.
Eighteen drugs were tested on the 34 RCTs. The 
average sample size was 98.9 ± 38.0 patients per study 
(CI = 83.7 to 114.1). The mean general rate of cure per drug 
was 83.0% ± 16.1 (CI = 78.4 to 87.6). Interestingly, the mean 
rate of cure of the placebo was 25%.
There was no significant difference either in the sample 
size/patient relationship or in the rate of cure observed between 
nonrandomized and RCTs studies (83.3 × 98.9 patients/study 
and 85.5% × 83.0%; p  0.05).
The most frequently tested drugs in RCTs were: 
metronidazole (21 studies, 61.8%), tinidazole (10 studies, 
29.4%), albendazole (nine studies, 26.5%), mebendazole (eight 
studies, 23.5%), ornidazole, furazolidone, and nitazoxanide 
(three studies each, 8.8%) (Table 10).
Among drugs showing greater effectiveness, the 
following mean rates of cure were found: ornidazole 
(RC = 97.6% ± 2.5), tinidazole (RC = 91.1% ± 6.3), 
metronidazole (RC = 81.5% ± 18.6), nitazoxanide 
(RC = 79.7% ± 1.8), and albendazole (RC = 73.4% ± 19.8) 
(Table 11). According to the nonrandomized clinical trials, 
metronidazole was the drug most frequently studied and 
Table 4 (Continued)
Year Drugs Activity Reference
2002 Metronidazole
Ornidazole single dose
Ornidazole five days
Yes (- effective)
Yes (+ effective)
Yes (+ effective)
115
2003 Mebendazole
Secnidazole
Yes
Yes
116
2003 Albendazole
Tinidazole
Cloroquine
Yes (- effective)
Yes (+ effective)
Yes (+ effective )
Tinidazole and Cloroquine 
with similar effectiveness and 
greater than Albendazole
117
2004 Metronidazole
Albendazole
Yes
Yes
118
2004 Metronidazole
Albendazole
Yes (- effective)
Yes (+ effective)
119
2006 Metronidazole + saccharomyces 
boulardii
Metronidazole +placebo
Yes (+ effective)
Yes (- effective)
120
2006 Mebendazole
Quinacrine
Yes
Yes
121
2006 Mebendazole
Tinidazole
Yes (- effective)
Yes (+ effective)
122
2006 Metronidazole
Albendazole
Yes (- effective)
Yes (+ effective)
123
2007 vitamin A
Zinc
vitamin + zinc
Placebo
Yes
Yes
Yes (+ effective)
No
124
2008 Tinidazole
Nitazoxanide
Yes (+ effective)
Yes (- effective)
125
Abbreviation: Se, side effects.Biologics: Targets & Therapy 2009:3 280
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Table 5 In vitro studies: drugs more frequently tested
Drugs/Substances tested Number of studies Observation
1 2,2-biimidazole 1 –
2 Human milk 1 –
3 Bithionol 1 –
4 Dichlorophene 1 –
5 Hexachlorophene 1 –
6 Clomipramine 1 –
7 Furazolidone 4 *
8 Nitroimidazole 1 –
9 Azitromicin 2 *
10 Doxiciclin 1 –
11 Mefloquin 1 –
12 Tinidazole 2 *
13 Metronidazole 9 *
14 Ornidazole 1 –
15 Serum immune specific 1 –
16 Agglutinin of wheat germ 1 –
17 Methanolic extracts cathartics 1 #
18 Methanolic extracts noncathartics 1 #
19 Albendazole 5 *
20 Pyrantel pamoate 1 –
21 Powder of Yucca schidigera 1 –
22 Ciprofloxacin 1 –
23 Nitazoxanide (Nitrotiazol) 2 *
24 Mucin 1 –
25 Derivatives of isoflavone 1 –
26 Derivative etylphenylcarbamate 2 *
27 Gangliosides 1 –
28 Dodecanoic acid 1 –
29 Arsenic sodium 1 –
30 Derivatives benzimidazoles 1 –
31 venom Crotalus durissus terrificus 1 –
32 venom Bothrops jararaca 1 –
33 Propolis 1 –
34 Curcumin 1 –
35 Analogous MTZ-Ms 1 –
36 Analogous MTZ-i 1 –
37 Analogous MTZ-Br 1 –
38 Analogous MTZ-N3 1 –
39 Analogous MTZ-NH3Cl 1 –
40 extracts of blueberry 1 –
41 Tiliroside 1 –
42 Kaempferol-glucopyranoside 2 *
43 Astragalin 1 –
44 Quercitrin 1 –
45 Isoquercitrin 1 –
46 Dorstenia contrajerva 1 –
47 Senna villosa 1 –
48 ruta chalepensis 1 –
(Continued)Biologics: Targets & Therapy 2009:3 281
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Table 5 (Continued)
Drugs/Substances tested Number of studies Observation
49 Derivatives of flavonoid glycosides 1 –
50 Derivatives of Artemisia ludoviciana 1 –
51 S-substituted 4,6-dibromo mercaptobenzimidazole 1 –
52 S-substituted 4,6-dichloro-2-mercaptobenzimidazole 1 –
53 Derivatives of flavonoid Helianthenum glomeratum 1 –
54 Derivatives of allicin (diallyl trisulfide) 1 –
55 Quinacrin 1 –
Notes: #phytotherapies are popular in Africa; *Drugs more frequently tested.
tested on the RCTs. Likewise, this drug had greater efficacy 
with larger doses and with more prolonged regimes (5 to 
10 days), reaching cure rates of 89% to 97% with these 
schemes (Table 12).
On the RCTs, tinidazole and ornidazole were the drugs 
which showed good efficacy using a single-dose scheme. 
Albendazole shown great variability in efficacy, not only 
in a single dose (RC = 50% to 97%), but also in prolonged 
regimes (RC = 62% to 90%).
The side effects were poorly described in the majority of 
studies in the nonrandomized control trials, and they ranged 
from none to 59%, although they were mild and transient. 
As in nonrandomized clinical trials, the prevalence of side 
effects were poorly described in the majority of RCTs studies, 
ranging from few or absent to 70%, and were also mild and 
transient.
Discussion
In 1957, the Rhone-Poulenc laboratories synthesized 
1-(β-hydroxyethyl)-2-methyl-5-nitroimidazole (metronidazole) 
by manipulating the chemical structure of 2-nitroimidazole126 
and this proved to be a highly effective agent against 
Trichomonas vaginalis infections.127 In 1962, Darbon and 
colleagues128 reported that this could also be used in treatments 
against giardiasis. Thus, since it was discovered, metronidazole 
and other 5-nitroimidazoles – such as secnidazole, ornidazole, 
and tinidazole – are used by physicians to treat G. lamblia 
infections in addition to infections by other microorganisms. 
Nowadays, metronidazole is the most used drug to treat giardia-
sis worldwide; including in the USA.129 However, the number 
of new drugs is increasing.
Doing this review, we found out that there were a high 
number of studies regarding the giardiasis treatment, even 
with the methodology used in the present study. However, 
the quality of them was very poor, mainly regarding their 
primary goal, their design, and sample size; in addition to a 
great heterogeneity detected between studies.
In all categories of studies, 298 were initially included 
(in vitro, in vivo, nonrandomized clinical trials, and RCTs), 
which, after selection, comprised 105 studies – representing 
35.2% – that constituted the sample for the analysis. It is 
important to point out that we used relatively liberal criteria 
to select the articles, and the search was done only in the 
most important databases, comprising journals with more 
restricted and rigorous publication criteria.
One hundred and sixteen references to in vitro studies 
were found, which comprised 39 (33.6%) studies that con-
stituted the data bank for analysis. Based on this, 50 drugs 
were evaluated, 48 (96%) of which showing activity against 
Giardia. Most of these studies had design to compare drugs 
among themselves (53 %): 52.4% to compare two drugs, and 
47.6% to compare three or more drugs.
Many of the studies with two or more drugs did not neces-
sarily compare the efficacy between drugs, but just analyzed 
and described the activity of the drugs without comparing 
their efficacy.
Although the number of known drugs tested was larger, 
we found out that the most widely tested drugs were metroni-
dazole, albendazole, and furazolidone, and that the new drugs 
were larger in number, each with few studies (Table 5). In this 
context, several in vitro studies have been carried out in order 
to search for new substances with antigiardial activity. This 
way, many methods have been described aiming at deter-
mining the antigiardial activity of drugs in vitro.4,19,64,130–133 
However, some of these are laborious and require long and 
hard work; furthermore, they are very difficult to reproduce 
for they lack standardization.
In the initial search for new drugs with antigiardial activ-
ity, 48 in vivo studies were found but only nine (18.8%) 
constituted the data bank for analysis, according to the 
inclusion criteria. Ten drugs were tested in these studies, 
and eight (80%) were active against Giardia. The majority 
of studies did not compare drugs, but just tested the activity 
of one drug against Giardia (Tables 2 and 6).Biologics: Targets & Therapy 2009:3 282
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Again, the various models used and the absence of 
standardized design, besides the heterogeneity of these 
studies, make the comparative analysis difficult. In this con-
text, several in vivo experimental models have been proposed. 
They are often beavers, young and adult rats,134–137 rabbits,138 
dogs,139 cats,140 mice,141,142 and gerbils.143,144 However, the 
best results have only been obtained in gerbil experimental 
models. Gerbil (Meriones unguiculatus) is considered by 
several researchers the most appropriate experimental model 
for giardiasis due to its size, facility to handle, high suscep-
tibility to infections, and large shedding of cysts in their 
feces.143–148 Thus, we consider that the absence of standardized 
methods between studies limited the comparative analysis.
When we analyze the studies in human beings (nonran-
domized trials and randomized control trials), we find great 
heterogeneity among them, besides the poor quality of their 
methodology.
No references selected were similar in design, dosages, 
duration of treatment, and results, which led to a great 
difficulty in grouping them according to the tested drug 
(required time or percentage of fecal cure, independent of 
duration of treatment). These findings agree with those by 
Zaat and colleagues.149
In the nonrandomized clinical trials, slightly more than 
a quarter of studies compared the efficacy between drugs, 
whereas 47.8% tested drugs without comparing them to a 
placebo or to another drug, just appraising their efficacy 
in treated patients versus untreated patients. Only 13% 
compared a drug to a placebo.
On the RCTs, we find that two thirds of the studies 
(67.6%) compared the efficacy between drugs; however, 
only 14.7% compared drugs to a placebo. Here, just one 
study did not include a comparison between drugs. About 
half the nonrandomized clinical trials tested different dosages 
of drugs (assessment of therapeutic schemes), whereas the 
RCTs were comparative studies of efficacy between drugs, 
with few studies using a placebo for comparing the efficacy 
of drugs (14.7%).
Regarding the number of drugs tested, we built an 
extensive list of them: 55 drugs in 39 in vitro studies, nine 
Table 6 In vivo studies: drugs more frequently tested
Drugs tested Number of studies Observation
1 Albendazole 1 –
2 News oxadiazoles 1 –
3 Metronidazole 1 –
4 ivermectin 2 *
5 Disulfiram (Antabuse) 1 –
6 Oxifendazole 1 –
7 inmunoglobulin (igA) 1 –
8 vaccine against Giardia 1 –
9 Antioxidant (Antox) 1 –
Note: *Drugs more frequently tested.
Table 7 Drugs more frequently tested in nonrandomized clinical 
trials
Drugs tested Number of studies Observation
1 Berberine 2 *
2 Metronidazole 9 *
3 Tinidazole 7 *
4 Nimorazole 1 –
5 Furazolidone 2 *
6 Tiberal 1 –
7 Quinacrin 3 *
8 Ornidazole 3 *
9 Diloxanide 1 –
10 Pippali rasayana 1 –
11 Albendazole 1 –
12 Secnidazole 2 *
Note: *Drugs more frequently tested.
Table 8 Mean rate of cure of drugs more tested in nonrandomized 
clinical trials
Drugs tested Number 
of studies
Mean rate of  
cure % ± SD (CI)
1 Metronidazole 9 76.6 ± 20.6 (64.9–88.3)
2 Tinidazole 7 89.1 ± 8.8 (83–92.5)
3 Ornidazole 3 93.6 ± 1.2 (92.2–95)
4 Quinacrin 3 85 ± 21.6 (63.8–100)
5 Secnidazole 2 96 ± 2.8 (92.0–99.9)
6 Furazolidone 2 82 ± 14.0 (62.5–100)
Note: *Drugs more frequently tested.
Abbreviations: CI, confidence interval; SD, standard deviation.
Table 9 More effective doses of drugs tested in nonrandomized 
clinical trials
Drugs Unit Recommended doses
Metronidazole mg/Kg/day 15–25 TiD – 5 to 10 days
mg 200–500 TiD – 5 to 10 days
Tinidazole mg 1–2 MiD – One day
Ornidazole mg 2 MiD – One day
Quinacrine mg 100 TiD – 5 days
Secnidazole mg/Kg 30 MiD – One day
Abbreviations: TiD, three times a day; MiD, once a day.Biologics: Targets & Therapy 2009:3 283
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drugs in nine in vivo studies, 12 drugs in 23 nonrandomized 
trials, and 18 drugs in 50 RCTs (Tables 1–4).
Regarding the sample size, in human studies, we found 
a comparatively small sample size in both nonrandomized 
and RCTs studies. We found a higher sample size in 
the RCTs as compared to the nonrandomized studies, 
though not statistically significant (98.9 × 83.3 patients/
study; p  0.05).
These findings show a great number of studies in which 
the external validation, and, consequently, the generalizability 
of the results is jeopardized. Numerous confounding factors 
make the analysis of these studies difficult, mainly due to 
problems in controlling some variables in the population 
studied.
The most frequently tested drugs in the present review 
are listed in Tables 5, 6, 7, and 10. We find that the most used 
drugs in human studies were all tested in in vitro studies, but 
not all drugs tested in in vivo studies were tested in human 
studies, although the number of drugs in the in vivo studies 
was as low as 10 drugs. Metronidazole was the most frequently 
tested drug. They were tested in 16.4% of in vitro studies, in 
11.1% of in vivo studies, in 39.1% of nonrandomized studies, 
and in 61.8% of RCTs. Thus, this drug was the main drug in 
the available arsenal for giardiasis treatment, constituting a 
reference in relation to other drugs. This finding corroborates 
other reviews.149,150
When only the nonrandomized and RCTs studies were 
analyzed, the two most tested drugs were metronidazole and 
tinidazole. However, mebendazole and albendazole were 
among the most tested in RCTs, and they were barely tested 
in nonrandomized studies.
We also noticed that the “new drugs” for giardiasis treatment 
were barely tested in all categories of studies reviewed in this 
work, either in in vitro studies or in RCTs. This demonstrates 
the difficulty in adequately testing one drug for giardiasis in 
order to have alternatives in case of resistance to one of the 
therapeutic schemes.
In spite of the large amount of drugs used in antigiardial 
therapy, some resistance has been reported regarding different 
therapeutic regimens, and this resistance has been mentioned 
by clinicians.18,20,151 This characteristic makes Giardia a 
fearful microorganism, mainly among undernourished 
people, in whom the malabsorption syndrome is more 
common. In this scenario, developing and screening new 
antigiardial drugs seems to be a priority.
Table 10 Drugs more frequently tested in randomized control 
clinical trials
Drugs tested Number 
of studies
Observation
1 Mepacrine 1 –
2 Metronidazole 21 *
3 Furazolidone 3 *
4 Tinidazole 10 *
5 Mebendazole 8 *
6 Ornidazole 3 *
7 Albendazole 9 *
8 Bacitracin zinc 1 –
9 Neomycin 1 –
10 Nitazoxanide 3 *
11 wheat germ 1 –
12 Praziquantel 1 –
13 Cloroquine 1 –
14 Secnidazole 1 –
15 Saccharomyces boulardii 1 –
16 Quinacrin 1 –
17 vitamin A 1 –
18 Zinc 2 –
Note: *Drugs more frequently tested.
Table 11 Mean rate of cure of drugs in randomized control clinical 
trials
Drugs tested Number 
of studies
Mean rate of  
cure % ± SD (CI)
1 Metronidazole 21 81.5 ± 18.6 (71.0–92.0)
2 Tinidazole 10 91.1 ± 6.3 (87.2–95.0)
3 Albendazole 9 73.4 ± 19.8 (58.7–88.1)
4 Mebendazole 8 65.6 ± 17.3 (50.4–80.8)
5 Ornidazole 3 97.6 ± 2.5 (95.4–99.8)
6 Nitazoxanide 3 79.7 ± 1.8 (77.2–82.2)
Note: *Drugs more frequently tested.
Abbreviations: CI, confidence interval; SD, standard deviation.
Table 12 More effective doses of drugs tested in randomized 
clinical trials
Drugs Unit Recommended doses
Metronidazole mg/Kg/day
mg
15–50 TiD – 5 to 10 days
500–750 TiD – 5 to 10 days
Tinidazole mg
mg/Kg/day
2 MiD – One dose
50 MiD – One dose
Albendazole mg
mg
mg/Kg/day
400 MiD – One day
400 MiD – 5 days
10 MiD – 5 days
Mebendazole mg 200 TiD – 5 days
Ornidazole mg/Kg/day 20–40 MiD – 1 to 5 days
Nitazoxanide mg 500 MiD – 3 days
Abbreviations: TiD, three times a day; MiD, once a day.Biologics: Targets & Therapy 2009:3 284
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In order to analyze the optimal dosages for the most 
tested drugs, we evaluated the mean rate of cure for all 
(Tables 8 and 11). We found out that the most tested drugs 
and those with more efficacy in studies with human beings 
were tinidazole and metronidazole; though ornidazole had a 
great efficacy not only in nonrandomized but also in RCTs. 
However, ornidazole was tested in only six studies in the 
present review (three nonrandomized and three RCTs).
The optimal dosages found in this review for most drugs 
were those that achieved the best rate of cure for each drug 
separately. Tables 8, 9, 11, and 12 show the most widely used 
drugs and their mean rate of cure, along with the optimal 
dosages for each. Comparing the mean rate of cure between 
the most tested drugs, we detected a similar efficacy among 
them, none being better than the others, except for meben-
dazole in the RCTs.
The analyses of the side effects have been poorly 
appraised and documented in most studies. Apparently, they 
have been similar in all studies, and no drug was reported 
to be unsafe, causing only mild to moderate and transient 
side effects.
However, regarding the new drugs, only those tested in 
human beings had their side effects described, but we have 
few data about it at the moment.
In summary, in this review we found many studies on 
the giardiasis treatment; however, most of them presented 
various problems concerning the sample size, methodology, 
design, among others.
Moreover, the number of drugs tested was large, with 
a relative higher number of new drugs listed, mainly in 
the in vitro studies, and a lower number in the studies with 
humans. However, these new drugs were barely tested as 
compared to the old drugs, mainly in humans, increasing the 
need for new studies to provide standardization for the evalu-
ation of antigiardial drugs. This can provide more accuracy 
and quickness for approval, as well as an adequate use not 
only for the new drugs but also the old ones.
Conclusion
In conclusion, this review raises some problems regarding the 
evidence for using old and new antigiardial drugs, in relation 
to the quality of previous and future studies. Yet, one must 
point out that the drugs in use nowadays are the most widely 
tested and that they are safe, although we must rethink and 
further study the problem of their increasing resistance.
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